Delhi HC resumes trial in Glenmark-Merck Sharp and Dohme patent case
The dispute is regarding the manufacturing of sitagliptin, a key active molecule in Glenmark’s anti-diabetes drug
New Delhi: The Delhi high court on Monday began hearing arguments in a patent dispute between Glenmark Pharmaceuticals Ltd and US-based Merck Sharp and Dohme, a unit of Merck and Co. Inc. The dispute is regarding the manufacturing of sitagliptin, a key active molecule in Glenmark’s anti-diabetes drug.
Merck Sharp and Dohme in 2013 moved the high court against Glenmark, alleging patent infringement. Judge Rajiv Sahai Endlaw refused to grant an injunction against Glenmark, but a two-judge bench of the high court later reversed this position, finding merit in Merck’s plea.
Glenmark then approached the apex court, where at a preliminary stage, the court stayed the Delhi high court’s ruling.
On 15 May, a bench comprising justices Ranjan Gogoi and N.V Ramana asked the trial judge of the Delhi high court to hear the patent dispute on a day-to-day basis to conclude the trial.
The matter is now being considered by Justice A.K. Pathak of the Delhi high court and both the parties have been ordered to finish arguments in a fixed time frame of five days each.
Editor's Picks »
- Market optimism before 2019 general election: History may not repeat itself
- UltraTech Cement: No respite from cost pressures
- Mindtree sees strong revenues but client concentration remains high
- Bandhan Bank’s share defies gravity as growth story is intact
- Fund managers slashing allocations to equities in emerging markets, shows BAML survey